Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cells Tissues Organs ; 205(4): 208-216, 2018.
Article in English | MEDLINE | ID: mdl-30121675

ABSTRACT

The aim of this study is to demonstrate and compare the differentiation, proliferation, migration and inflammatory behavior of dental pulp- and bone marrow-derived mesenchymal stem cells (DP-MSCs and BM-MSCs) in response to a Hypericum perforatum ethanol extract. Using xCELLigence, a real-time monitoring system, a dose of 10 µg/mL was found to be the most efficient concentration for vitality. The IC50 values and doubling time were calculated. The results showed that H. perforatum L. was able to accelerate osteogenic differentiation in DP-MSCs, but calcium granulation was impaired in BM-MSCs. H. perforatum L.-induced migration increased when compared to the TNF-α-induced migration in a Transwell migration assay, and the IL-6 cytokine levels between cells also differed. It can be suggested that tissue memory is an important factor in MSCs, and that they differ in their response to external factors. In conclusion, H. perforatum L. can be considered an excellent osteoinductive agent for DP-MSCs but should not be used for BM-MSCs. Tissue-specific osteoinductive agents should be discussed in future studies.


Subject(s)
Hypericum/chemistry , Mesenchymal Stem Cells/drug effects , Osteogenesis/drug effects , Adolescent , Adult , Cell Differentiation , Cell Movement , Cell Proliferation , Female , Humans , Male , Mesenchymal Stem Cells/metabolism , Young Adult
2.
J Appl Oral Sci ; 25(5): 515-522, 2017.
Article in English | MEDLINE | ID: mdl-29069149

ABSTRACT

INTRODUCTION: Hypersensitivity, local irritative and cytotoxic effects are known for the chemical components of Syzygium aromaticum and Cinnamomum zeylanicum contained in dental materials. However, there is no intimate data in dentistry using the whole extracts of these plants and introducing new ones. Salvia triloba is a well-known anti-inflammatory plant that correspondingly could be used in several dental traumas. OBJECTIVES: We aimed to show and compare the effect of S. aromaticum, C. zeylanicum, and S. triloba extracts on dental pulp stem cells (DPSCs) proliferation, differentiation, and immune responses. MATERIAL AND METHODS: Using xCELLigence, a real time monitoring system, we obtained a growth curve of DPSCs with different concentrations of the Extracts. A dose of 10 µg/mL was the most efficient concentration for vitality. Osteogenic differentiation and anti-inflammatory activities were determined by using an ELISA Kit to detect early and late markers of differentiation. RESULTS: The level of osteonectin (ON, early osteogenic marker) decreased, which indicated that the osteogenic differentiation may be accelerated with addition of extracts. However, the level of osteocalcin (OCN, late osteogenic marker and sign of calcium granulation) differed among the extracts, in which S. aromaticum presented the highest value, followed by S. triloba and C. zeylanicum. Surprisingly, the determined calcium granules were reduced in S. aromaticum and S. triloba. In response to tumor necrosis factor alpha (TNF-α), S. triloba-treated DPSCs showed the most reduced level of IL-6 cytokine level. We suggest C. zeylanicum as a promising osteogenic inducer and S. triloba as a potent anti-inflammatory agent, which could be used safely in biocomposite or scaffold fabrications for dentistry. CONCLUSIONS: Because calcium granule formation and cell viability play a critical role in hard tissue formation, S. aromaticum in dentistry should be strictly controlled, and the mechanism leading to reduced calcium granule formation should be identified.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Cinnamomum zeylanicum/chemistry , Dental Pulp/cytology , Drugs, Chinese Herbal/pharmacology , Mesenchymal Stem Cells/drug effects , Plant Extracts/pharmacology , Syzygium/chemistry , Adolescent , Analysis of Variance , Antigens, Differentiation/analysis , Calcium/analysis , Camphanes , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Cytokines/analysis , Dental Pulp/drug effects , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Humans , Osteocalcin/analysis , Osteogenesis/drug effects , Osteonectin/analysis , Panax notoginseng , Reproducibility of Results , Salvia miltiorrhiza , Time Factors , Young Adult
3.
Ophthalmic Surg Lasers Imaging Retina ; 46(4): 471-4, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25932725

ABSTRACT

BACKGROUND AND OBJECTIVE: The aim of the study was to evaluate vitreous incarceration at the injection site using ultrasound biomicroscopy (UBM) after intravitreal injection of ranibizumab. PATIENTS AND METHODS: The study included 39 eyes of 34 patients who underwent intravitreal injection of 0.05 mL of ranibizumab. UBM (HiScan; Optikon, Rome, Italy) with a 50 MHz probe was performed 1 day after surgery to determine the existence of vitreous incarceration at the injection site. RESULTS: The mean patient age was 59.7 (± 10.1) years, and 58.9% were female. Vitreous incarceration into the pars plana site was detected in six eyes (15.3%) the day after intravitreal injection. CONCLUSION: Vitreous incarceration at the injection site after intravitreal injection is thought to lead to a higher risk for complications such as infection, retinal breaks, retinal detachment, vitreous hemorrhage, and fibrovascular proliferation at the injection site. To understand the clinical importance of vitreous incarceration, further long-term prospective studies are necessary.


Subject(s)
Angiogenesis Inhibitors/administration & dosage , Antibodies, Monoclonal, Humanized/administration & dosage , Eye Diseases/diagnostic imaging , Intraoperative Complications , Intravitreal Injections/adverse effects , Microscopy, Acoustic , Vitreous Body/diagnostic imaging , Adult , Aged , Aged, 80 and over , Eye Diseases/etiology , Female , Humans , Macular Degeneration/drug therapy , Macular Edema/drug therapy , Male , Middle Aged , Prospective Studies , Ranibizumab , Retinal Vein Occlusion/drug therapy , Sclera , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Vitreous Body/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...